CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Dr. Christopher J. Hoimes, Associate Professor of Medicine-GU Oncology at Duke University, presents data on the KEYNOTE-045 Phase 3 Trial, which demonstrated that patients treated with KEYTRUDA (pembrolizumab) had a 27% reduction in risk of death compared to patients treated with chemotherapy.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
